GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » Total Liabilities

PHCUF (PhotoCure ASA) Total Liabilities : $20.15 Mil (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is PhotoCure ASA Total Liabilities?

PhotoCure ASA's Total Liabilities for the quarter that ended in Jun. 2024 was $20.15 Mil.

PhotoCure ASA's quarterly Total Liabilities increased from Dec. 2023 ($21.72 Mil) to Mar. 2024 ($21.82 Mil) but then declined from Mar. 2024 ($21.82 Mil) to Jun. 2024 ($20.15 Mil).

PhotoCure ASA's annual Total Liabilities declined from Dec. 2021 ($31.96 Mil) to Dec. 2022 ($25.94 Mil) and declined from Dec. 2022 ($25.94 Mil) to Dec. 2023 ($21.72 Mil).


PhotoCure ASA Total Liabilities Historical Data

The historical data trend for PhotoCure ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA Total Liabilities Chart

PhotoCure ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.40 30.77 31.96 25.94 21.72

PhotoCure ASA Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.14 22.07 21.72 21.82 20.15

PhotoCure ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PhotoCure ASA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.882+(1.325+12.102
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.41)
=21.72

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=67.489-45.77
=21.72

PhotoCure ASA's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.279+(0+13.873
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=20.15

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=67.221-47.07
=20.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhotoCure ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


PhotoCure ASA Business Description

Traded in Other Exchanges
Address
Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.